Literature DB >> 20025683

Chronic kidney disease in Tasmania.

Matthew D Jose1, Petr Otahal, Geoff Kirkland, Leigh Blizzard.   

Abstract

AIM: Chronic kidney disease (CKD) is a progressive disease which is becoming a major public health issue due to its high rate of premature death, poor quality of life and expensive end-stage treatment (dialysis or transplantation). The burden of this chronic condition in a community setting was examined.
METHODS: Data were obtained from 369,098 Tasmanian adults (aged >or=18 years) and included 1,640,687 measurements of creatinine taken between 1995 and 2007. In 2007 alone, testing comprised 25.5% of the state's adult population. A modelled estimate of CKD prevalence was developed.
RESULTS: For those at risk of CKD (aged >50 years), 50.6%, 70.2% and 82% had a measured creatinine (and reported estimated glomerular filtration rate (eGFR)) during the last 1, 2 and 3 years respectively. However, only 9.4% of people with eGFR of less than 60 mL/min per 1.73 m(2) had albuminuria formally measured. Estimated prevalence of stage III or greater CKD (eGFR <60 mL/min per 1.73 m(2)) was at least 11.4% of women and 8.6% of men during 2007. Detection of low eGFR increased significantly over the last 13 years. There was a large geographic variation throughout Tasmania and high relative mortality with lower eGFR. There is a broad gap between the number of people with eGFR of less than 15 mL/min per 1.73 m(2) (stage V CKD) and those receiving dialysis treatment.
CONCLUSION: The number of people identified with low eGFR has increased significantly since 1995 with a large geographic variation. Despite this, testing for kidney disease (by measuring serum creatinine and albuminuria) in people at risk is still suboptimal.

Entities:  

Mesh:

Year:  2009        PMID: 20025683     DOI: 10.1111/j.1440-1797.2009.01198.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  9 in total

1.  Impact of the pharmacist medication review services on drug-related problems and potentially inappropriate prescribing of renally cleared medications in residents of aged care facilities.

Authors:  Pankti A Gheewala; Gregory M Peterson; Colin M Curtain; Prasad S Nishtala; Paul J Hannan; Ronald L Castelino
Journal:  Drugs Aging       Date:  2014-11       Impact factor: 3.923

2.  A web-based training program to support chronic kidney disease screening by community pharmacists.

Authors:  Pankti A Gheewala; Gregory M Peterson; Syed Tabish R Zaidi; Luke Bereznicki; Matthew D Jose; Ronald L Castelino
Journal:  Int J Clin Pharm       Date:  2016-06-21

3.  Island medicine: using data linkage to establish the kidney health of the population of Tasmania, Australia.

Authors:  Matthew Jose; Rajesh Raj; Kim Jose; Alex Kitsos; Tim Saunder; Charlotte McKercher; Jan Radfor
Journal:  Int J Popul Data Sci       Date:  2021-08-03

Review 4.  Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis.

Authors:  Nathan R Hill; Samuel T Fatoba; Jason L Oke; Jennifer A Hirst; Christopher A O'Callaghan; Daniel S Lasserson; F D Richard Hobbs
Journal:  PLoS One       Date:  2016-07-06       Impact factor: 3.240

5.  Chronic Kidney Disease in Tasmania: Protocol for a Data Linkage Study.

Authors:  Timothy Saunder; Alex Kitsos; Jan Radford; Kim Jose; Charlotte McKercher; Rajesh Raj; Nadine Wiggins; Brian Stokes; Matthew D Jose
Journal:  JMIR Res Protoc       Date:  2020-09-17

6.  Psychosocial factors in adults with chronic kidney disease: characteristics of pilot participants in the Tasmanian Chronic Kidney Disease study.

Authors:  Charlotte M McKercher; Alison J Venn; Leigh Blizzard; Mark R Nelson; Andrew J Palmer; Michael A Ashby; Jennifer L Scott; Matthew D Jose
Journal:  BMC Nephrol       Date:  2013-04-12       Impact factor: 2.388

7.  Chronic kidney disease in the Top End of the Northern Territory of Australia, 2002-2011: a retrospective cohort study using existing laboratory data.

Authors:  Paul D Lawton; Joan Cunningham; Narelle Hadlow; Yuejen Zhao; Matthew D Jose
Journal:  BMC Nephrol       Date:  2015-10-22       Impact factor: 2.388

Review 8.  CKD Screening and Surveillance in Australia: Past, Present, and Future.

Authors:  Sree K Venuthurupalli; Wendy E Hoy; Helen G Healy; Anne Cameron; Robert G Fassett
Journal:  Kidney Int Rep       Date:  2017-10-06

9.  Australian Community Pharmacists' Experience of Implementing a Chronic Kidney Disease Risk Assessment Service.

Authors:  Pankti A Gheewala; Gregory M Peterson; Syed Tabish R Zaidi; Matthew D Jose; Ronald L Castelino
Journal:  Prev Chronic Dis       Date:  2018-06-14       Impact factor: 2.830

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.